Cortexyme: Addressing Unmet Needs in the Alzheimer’s Market
The stocks of Cortexyme, Inc (NASDAQ: CRTX), a clinical stage biopharmaceutical company engaged in developing novel therapeutics for Alzheimer’ disease, surged by almost 70% on its debut on the stock market on May 9. Its market value jumped to $750 million by end of trading...
